Perspective | Published:

The brain and immune system prompt energy shortage in chronic inflammation and ageing

Nature Reviews Rheumatology volume 13, pages 743751 (2017) | Download Citation

Abstract

Sequelae frequently seen in patients with chronic inflammatory diseases, such as fatigue, depressed mood, sleep alterations, loss of appetite, muscle wasting, cachectic obesity, bone loss and hypertension, can be the result of energy shortages caused by an overactive immune system. These sequelae can also be found in patients with chronic inflammatory diseases that are in remission and in ageing individuals, despite the immune system being less active in these situations. This Perspectives article proposes a new way of understanding situations of chronic inflammation (such as rheumatic diseases) and ageing based on the principles of evolutionary medicine, energy regulation and neuroendocrine–immune crosstalk. A conceptual framework is provided to enable physicians and scientists to better understand the signs and symptoms of chronic inflammatory diseases and long-term disease consequences resulting from physical and mental inactivity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , & Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J. Intern. Med. 267, 543–560 (2010).

  2. 2.

    , , , & Nutritional habits of patients suffering from seropositive rheumatoid arthritis: a screening of 93 Dutch patients. Clin. Rheumatol. 9, 483–488 (1990).

  3. 3.

    , & Dietary intake and nutritional status in patients with systemic sclerosis. Ann. Rheum. Dis. 51, 1143–1148 (1992).

  4. 4.

    The anorexia of aging. Clin. Geriatr. Med. 23, 735–756 (2007).

  5. 5.

    & Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 21, 153–160 (2007).

  6. 6.

    et al. MicroRNAs linking inflamm-aging, cellular senescence and cancer. Ageing Res. Rev. 12, 1056–1068 (2013).

  7. 7.

    & Premature immunosenescence in rheumatoid arthritis. J. Rheumatol. 29, 1141–1146 (2002).

  8. 8.

    , & The multiple facets of premature aging in rheumatoid arthritis. Arthritis Rheum. 48, 2713–2721 (2003).

  9. 9.

    et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J. Clin. Invest. 93, 2379–2386 (1994).

  10. 10.

    , , , & Total free living energy expenditure in patients with severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 155, 549–554 (1997).

  11. 11.

    et al. Resting energy expenditure in chronic hepatitis C. J. Hepatol. 33, 623–627 (2000).

  12. 12.

    , , & Bioenergetics of immune cells to assess rheumatic disease activity and efficacy of glucocorticoid treatment. Ann. Rheum. Dis. 62, 133–139 (2003).

  13. 13.

    et al. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 66, 54–62 (1997).

  14. 14.

    et al. Effects of endotoxin on lactate metabolism in humans. Crit. Care 16, R139 (2012).

  15. 15.

    & Chronic inflammatory systemic diseases: an evolutionary trade-off between acutely beneficial but chronically harmful programs. Evol. Med. Public Health. 2016, 37–51 (2016).

  16. 16.

    , , & Metabolism of stromal and immune cells in health and disease. Nature 511, 167–176 (2014).

  17. 17.

    & Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 493, 346–355 (2013).

  18. 18.

    , & Signaling takes a breath — new quantitative perspectives on bioenergetics and signal transduction. Immunity 15, 497–502 (2001).

  19. 19.

    & Immunometabolism in early and late stages of rheumatoid arthritis. Nat. Rev. Rheumatol. 13, 291–301 (2017).

  20. 20.

    & Innate immunity and adipose tissue biology. Trends Immunol. 31, 228–235 (2010).

  21. 21.

    The wisdom of the body (Norton & Company, 1939).

  22. 22.

    Integration of feeding and spontaneous physical activity: role for orexin. Physiol. Behav. 88, 294–301 (2006).

  23. 23.

    , & Principles of evolutionary medicine (Oxford Univ. Press, 2009).

  24. 24.

    & Evolutionary medicine (Sinauer Associates, 2016).

  25. 25.

    Energy metabolism in animals and man (Cambridge Univ. Press, 1989).

  26. 26.

    Time, structure, and fluctuations. Science 201, 777–785 (1978).

  27. 27.

    , & Neuronal control of peripheral insulin sensitivity and glucose metabolism. Nat. Commun. 8, 15259 (2017).

  28. 28.

    Inflammatory pathways and insulin action. Int. J. Obes. Relat. Metab. Disord. 27, S53–S55 (2003).

  29. 29.

    Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively selected program used in chronic inflammatory diseases. Arthritis Res. Ther. 16, S4 (2014).

  30. 30.

    & Molecular bases of the sympathetic regulation of bone mass. Bone 42, 837–840 (2008).

  31. 31.

    , , & Inflammatory osteolysis: a conspiracy against bone. J. Clin. Invest. 127, 2030–2039 (2017).

  32. 32.

    , & Evolutionary medicine and bone loss in chronic inflammatory diseases — a theory of inflammation-related osteopenia. Semin. Arthritis Rheum. 45, 220–228 (2015).

  33. 33.

    et al. The selfish brain: competition for energy resources. Neurosci. Biobehav. Rev. 28, 143–180 (2004).

  34. 34.

    & The intricate interface between immune system and metabolism. Trends Immunol. 25, 193–200 (2004).

  35. 35.

    & Regulation of T lymphocyte metabolism. J. Immunol. 172, 4661–4665 (2004).

  36. 36.

    , & Energy metabolism and rheumatic diseases: from cell to organism. Arthritis Res. Ther. 14, 216–225 (2012).

  37. 37.

    et al. Extracellular adenosine mediates a systemic metabolic switch during immune response. PLoS Biol. 13, e1002135 (2015).

  38. 38.

    Evolutionary medicine and chronic inflammatory state — known and new concepts in pathophysiology. J. Mol. Med. (Berl.) 90, 523–534 (2012).

  39. 39.

    , , & Daily energy requirements in heart failure patients. Metabolism 46, 1294–1298 (1997).

  40. 40.

    Energy intake and energy expenditure profiles in peritoneal dialysis patients. J. Ren Nutr. 21, 31–34 (2011).

  41. 41.

    & Adaptive memory: ancestral priorities and the mnemonic value of survival processing. Cogn. Psychol. 61, 1–22 (2010).

  42. 42.

    & Nutritional status, activity pattern, and dietary intake among the Baka hunter-gatherers in the village camps in Cameroon. Afr. Study Monogr. 21, 67–82 (2000).

  43. 43.

    & Modelling the mobility of living organisms in heterogeneous landscapes: does memory improve foraging success? Philos. Trans. A Math. Phys. Eng. Sci. 368, 5645–5659 (2010).

  44. 44.

    , & Janeway's Immunobiology (Taylor & Francis, 2011).

  45. 45.

    , & Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol. Today 21, 192–199 (2000).

  46. 46.

    & Immune-neuro-endocrine interactions: facts and hypotheses. Endocr. Rev. 17, 64–102 (1996).

  47. 47.

    et al. Leptin mediates the increase in blood pressure associated with obesity. Cell 159, 1404–1416 (2014).

  48. 48.

    et al. Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat. Rev. Rheumatol. 13, 100–109 (2017).

  49. 49.

    , , & Neural innervation of white adipose tissue and the control of lipolysis. Front. Neuroendocrinol. 35, 473–493 (2014).

  50. 50.

    , & Muscle reflex in heart failure: the role of exercise training. Front. Physiol. 3, 398 (2012).

  51. 51.

    , & Plasma leptin suppression by arginine vasopressin in normal women and men. Life Sci. 72, 1209–1220 (2003).

  52. 52.

    Muscle as a secretory organ. Compr. Physiol. 3, 1337–1362 (2013).

  53. 53.

    et al. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by β-adrenergic activation and effects of IL-6 on adipocyte function. J. Clin. Endocrinol. Metab. 86, 2281–2288 (2001).

  54. 54.

    et al. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am. J. Physiol. Endocrinol. Metab. 288, E155–E162 (2005).

  55. 55.

    et al. Effects of free fatty acids on hepatic glycogenolysis and gluconeogenesis in conscious dogs. Am. J. Physiol. Endocrinol. Metab. 282, E402–E411 (2002).

  56. 56.

    et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18, 343–354 (2003).

  57. 57.

    , , & Effect of late-onset sepsis on energy expenditure in extremely premature infants. Pediatr. Res. 61, 600–603 (2007).

  58. 58.

    et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J. Clin. Endocrinol. Metab. 83, 2012–2017 (1998).

  59. 59.

    et al. Life stress, mood disturbance, and elevated interleukin-6 in healthy older women. J. Gerontol. A Biol. Sci. Med. Sci. 54, M434–M439 (1999).

  60. 60.

    et al. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion. Arthritis Rheum. 48, 1504–1512 (2003).

  61. 61.

    & Resting energy expenditure in manic episode. Bipolar Disord. 11, 102–106 (2009).

  62. 62.

    , , & State-related differences in the level of psychomotor activity in patients with bipolar disorder — continuous heart rate and movement monitoring. Psychiatry Res. 237, 166–174 (2016).

  63. 63.

    et al. Energy balance in early-stage Huntington disease. Am. J. Clin. Nutr. 81, 1335–1341 (2005).

  64. 64.

    et al. Association between smoking and total energy expenditure in a multi-country study. Nutr. Metab. (Lond.) 11, 48–11 (2014).

  65. 65.

    & Smoking-related correlates of psychomotor restlessness and agitation in a community sample of daily cigarette smokers. Am. J. Addict. 24, 166–172 (2015).

  66. 66.

    et al. Increased energy expenditure and glucose oxidation during acute nontraumatic skin pain in humans. Eur. J. Anaesthesiol. 26, 311–317 (2009).

  67. 67.

    et al. Acute pain induces insulin resistance in humans. Anesthesiology 95, 578–584 (2001).

  68. 68.

    , , & Effect of postoperative analgesia on energy metabolism and role of cyclooxygenase-2 inhibitors for postoperative pain management after abdominal surgery in adults. Clin. J. Pain 29, 570–576 (2013).

  69. 69.

    et al. How the selfish brain organizes its supply and demand. Front. Neuroenergetics 2, 7–17 (2010).

  70. 70.

    et al. Work intensity during working hours and different types of care done by special nursing home workers [Japanese]. Nihon Eiseigaku Zasshi 52, 567–573 (1997).

  71. 71.

    , , , & Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber. J. Clin. Invest. 78, 1568–1578 (1986).

  72. 72.

    et al. Impact of insufficient sleep on total daily energy expenditure, food intake, and weight gain. Proc. Natl Acad. Sci. USA 110, 5695–5700 (2013).

  73. 73.

    et al. Energy expenditure during sleep, sleep deprivation and sleep following sleep deprivation in adult humans. J. Physiol. 589, 235–244 (2011).

  74. 74.

    et al. Resting energy expenditure in OSAS: the impact of a single CPAP application. Sleep Breath. 20, 121–128 (2016).

  75. 75.

    , , & Resting metabolic rate is influenced by anxiety in college men. J. Appl. Physiol. (1985) 80, 638–642 (1996).

  76. 76.

    Bodily changes in pain, hunger, fear, and rage (D. Appleton and Company, 1927).

  77. 77.

    & Associations between energy demands, physical activity, and body composition in adult humans between 18 and 96 y of age. Am. J. Clin. Nutr. 92, 826–834 (2010).

  78. 78.

    , & Are persons with rheumatoid arthritis deconditioned? A review of physical activity and aerobic capacity. BMC. Musculoskelet. Disord. 13, 202–213 (2012).

  79. 79.

    et al. Low physical activity reduces total energy expenditure in women with rheumatoid arthritis: implications for dietary intake recommendations. Am. J. Clin. Nutr. 76, 774–779 (2002).

  80. 80.

    , , & Physical activity for paediatric rheumatic diseases: standing up against old paradigms. Nat. Rev. Rheumatol. 13, 368–379 (2017).

  81. 81.

    et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376–381 (2014).

  82. 82.

    et al. HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever. Hum. Immunol. 63, 1039–1044 (2002).

  83. 83.

    Pleiotropy, natural selection, and the evolution of senescence. Evolution 11, 398–411 (1957).

  84. 84.

    et al. Physical activity in primary and secondary prevention of cardiovascular disease: overview updated. World J. Cardiol. 8, 575–583 (2016).

  85. 85.

    , , , & Combined effects of physical activity and obesity on cognitive function: independent, overlapping, moderator, and mediator models. Sports Med. 47, 449–468 (2017).

  86. 86.

    & Physical activity to reduce systemic inflammation associated with chronic pain and obesity: a narrative review. Clin. J. Pain 32, 365–370 (2016).

  87. 87.

    , , & Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling. Front. Cell. Neurosci. 8, 170 (2014).

  88. 88.

    , , , & The link between physical activity and cognitive dysfunction in Alzheimer disease. Phys. Ther. 95, 1046–1060 (2015).

  89. 89.

    et al. Exercise, physical activity, and sedentary behavior in the treatment of depression: broadening the scientific perspectives and clinical opportunities. Front. Psychiatry. 7, 36 (2016).

  90. 90.

    et al. Physical activity in older age: perspectives for healthy ageing and frailty. Biogerontology 17, 567–580 (2016).

  91. 91.

    et al. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ 354, i3857 (2016).

  92. 92.

    , , , & Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum. 63, 1–9 (2011).

  93. 93.

    et al. Altered lipid metabolism in vasopressin V1B receptor-deficient mice. Eur. J. Pharmacol. 602, 455–461 (2009).

Download references

Acknowledgements

R.H.S. would like to thank David Pisetsky of Duke University Medical Center, Durham, North Carolina, USA, who reviewed an early version of the manuscript and provided helpful editorial comments, and the team of Martin Fleck at University Hospital Regensburg, Regensburg, Germany, for discussing the clinical aspects of the present work during a seminar in 2016. The work of R.H.S. is supported financially by the Deutsche Forschungsgemeinschaft (DFG), the German Federal Ministry of Education and Research and the State of Bavaria (through local funding by University Hospital Regensburg).

Author information

Affiliations

  1. Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Franz Josef Strauß Allee 11, 93053 Regensburg, Germany.

    • Rainer H. Straub

Authors

  1. Search for Rainer H. Straub in:

Competing interests

The author declares no competing financial interests.

Corresponding author

Correspondence to Rainer H. Straub.

Supplementary information

PDF files

  1. 1.

    Supplementary information S1 (table)

    Adaptive programmes in chronic inflammatory diseases and during ageing that protect against energy shortages

Glossary

Context-associated anorexia

Anorexia that is dependent on a particular circumstance, such as sickness behaviour during an infection, mental activation in bipolar disorder or age-related anorexia.

Insulin resistance

A condition of low insulin sensitivity with marked changes to the insulin receptor and to downstream signalling pathways; because insulin is responsible for the storage of glucose and free fatty acids, a lower insulin sensitivity leads to reduced energy storage and increased levels of energy-rich fuels in the circulation.

Pro-inflammatory load

A high level of systemic activity in the immune system, as measured by an increased erythrocyte sedimentation rate, or increased levels of serum C-reactive protein or serum IL-6.

Psychomotor activity

Activity induced by the brain that leads to activation of the skeletal muscles and the heart.

Super-systems

Integrative systems at the top level of homeostatic regulation of the body; examples include the nervous, endocrine and immune systems.

Thermodynamically open system

Systems, such as the human body, that can take up and lose energy, mainly in the form of heat.

State and trait anxiety

State anxiety is how a person is feeling at the time of a perceived threat, whereas trait anxiety is the enduring disposition to feel stress, worry and discomfort.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrrheum.2017.172

Further reading